Stocks Health care VBIO
NASDAQ · Health careValion Bio, Inc. (VBIO)
It posted a net loss of $18.8M. In fiscal 2025 capital spending exceeded operating cash flow by $7M. At June 30, 2026 it held $2.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
What Valion Bio, Inc. does
Valion Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VBIO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$8.9M | -$7.84 | -$7M |
| 2024 | $780K | -$5.7M | -$19.68 | -$5.7M |
| 2023 | $1.2M | -$8.2M | -$176.80 | -$8.6M |
| 2022 | $1.8M | -$10.1M | -$1,773.44 | -$8.9M |
| 2022 | $1.3M | -$8.5M | -$4,143.71 | n/a |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Valion Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 23, 2026
- September 4, 2026Passive stake changed SCHEDULE 13G/A
- September 3, 2026Activist stake changed SCHEDULE 13D/A
- September 2, 2026Activist stake changed SCHEDULE 13D/A
- September 1, 2026
- August 27, 2026Activist stake changed SCHEDULE 13D/A
- August 27, 2026
- August 24, 2026Activist stake changed SCHEDULE 13D/A
- August 24, 2026
- August 20, 2026Shareholder vote results 8-K/A
Insider trades
What the people running Valion Bio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 18, 2026 | Wolf Lisa GCOO & CFO | Exercised options | 4 | - |
| September 18, 2026 | Wolf Lisa GCOO & CFO | Shares withheld for tax | 2 | $4.2 |
| June 18, 2026 | Wolf Lisa GChief Financial Officer | Exercised options | 92 | - |
| May 18, 2026 | Handley Michael KChief Executive Officer, Director | Exercised options | 2,206 | - |
Who owns VBIO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Murchinson Ltd.13G, passive with 8 related filers | 9.99% | July 17, 2026 |
| 3i, LP13G, passive with 3 related filers | 9.9% | September 4, 2026 |
Largest institutional holders
Insiders
2 insiders reported holding 11,057 shares in total.
| Holder | Shares |
|---|---|
| Handley Michael KChief Executive Officer, Director | 11,030 |
| Wolf Lisa GCOO & CFO | 27 |
Questions about VBIO
What does Valion Bio, Inc. do?
Valion Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VBIO.
Is Valion Bio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $18.8M.
When did Valion Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 24, 2026.
Similar companies
Compare VBIO with
Follow VBIO
Get an email when Valion Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow VBIO: get an email when it filesWhere the numbers come from
Financial figures are the values Valion Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.